Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...
Bavarian Nordic Publishes Annual Report 2024 Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two...
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine...
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine Contract manufacturing agreement marks the first...
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine approved for persons as...
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025 Travel Health business demonstrated...
Bavarian Nordic – Completion of Share Buy-Back Program COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the...
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older First chikungunya vaccine recommended by the...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA...
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA...
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA...
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India Tech transfer of MVA-BN® will help...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads